Atrium Therapeutics, Inc. RNA
8.72 USD +0.17 (+1.99%)
At closeNov 3, 2026, 4:01 PM EST
8.72 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
8.45 Day range 8.77
7.49 52-week range 16.77
- YTD
- -40.88%
- 1 year
- -40.88%
- Market cap
- 149.16M
- Revenue (ttm)
- 18.62M
- Profit margin
- -265.88%
- EPS (ttm)
- -5.44
- Shares out
- 15.51M
- Forward P/E
- -3.67
- YTD return
- -40.88%
- 1-year return
- -40.88%
- Volume
- 280.93K
- Avg volume
- 285.05K
- Open
- 8.57
- Previous close
- 8.55
- Day's range
- 8.45 – 8.77
- 52-week range
- 7.49 – 16.77
2Y -6.03 (-40.88%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 12.35
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -71.10%
- Free cash flow
- -11.65M
- Total cash
- 0
- Total debt
- 3.67M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 15.47
- 200-day average
- 15.47
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RNA Revenue — quarterly 3.00M
RNA Net income — quarterly -20.19M
RNA EPS — quarterly -1.18
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2025 | Chardan Capital | main | Neutral | Neutral |
| Oct 29, 2025 | TD Cowen | down | Buy | Hold |
| Oct 28, 2025 | Chardan Capital | down | Buy | Neutral |
| Oct 28, 2025 | RBC Capital | down | Outperform | Sector Perform |
| Oct 27, 2025 | Citigroup | down | Buy | Neutral |
| Oct 27, 2025 | Leerink Partners | down | Outperform | Market Perform |
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known as Bryce Therapeutics, Inc. Atrium Therapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. operates as a subsidiary of Avidity Biosciences, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
News
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy 
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 
HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20 
Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027 
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome 
This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15 
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 
Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing 
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Your note
Sign in to keep a note on RNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOYCE SARAH | Chief Executive Officer | Sale | Jan 20, 2026 | 269,007 |
| CALDERARO CHARLES III | Officer | Sale | Jan 6, 2026 | 49,797 |
| FLANAGAN WILLIAM MICHAEL | Officer | Sale | Jan 20, 2026 | 85,093 |
| GALLAGHER KATHLEEN P | Officer | Stock Award(Grant) | Dec 16, 2025 | 80,838 |
| HUGHES STEVEN GEORGE | Officer | Sale | Jan 20, 2026 | 31,599 |
| LEVIN ARTHUR A. | Director | Sale | Jan 20, 2026 | 170,434 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 8.80% | 13,649,250 | 202.28M | Dec 30, 2025 |
| Blackrock Inc. | 8.28% | 12,850,801 | 190.45M | Dec 30, 2025 |
| RA Capital Management, L.P. | 5.57% | 8,641,031 | 128.06M | Dec 30, 2025 |
| Janus Henderson Group PLC | 4.47% | 6,939,503 | 102.84M | Dec 30, 2025 |
| Balyasny Asset Management LP | 3.89% | 6,040,590 | 89.52M | Dec 30, 2025 |
| Pentwater Capital Management Lp | 3.88% | 6,026,500 | 89.31M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.77% | 4,303,392 | 63.78M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.08% | 3,234,628 | 47.94M | Sep 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.88% | 2,921,656 | 43.30M | Dec 30, 2025 |
| T. Rowe Price New Horizons Fund, Inc. | 1.69% | 2,621,852 | 38.86M | Sep 29, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.63% | 2,531,865 | 37.52M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.33% | 2,070,296 | 30.68M | Sep 29, 2025 |